

# Michael A Kamm

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8769809/publications.pdf>

Version: 2024-02-01

197  
papers

18,974  
citations

14614

66  
h-index

11899

134  
g-index

199  
all docs

199  
docs citations

199  
times ranked

13477  
citing authors

#	ARTICLE	IF	CITATIONS
1	Endoscopic Prediction of Crohn's Disease Postoperative Recurrence. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 680-688.	0.9	13
2	Prevalence of disordered eating in adults with gastrointestinal disorders: A systematic review. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14278.	1.6	17
3	Diet and gut microbiome in gastrointestinal disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 237-245.	1.4	25
4	P449 Autologous fat graft injection for the treatment of perianal fistulas in Crohn's disease: A systematic review and single-arm meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i428-i429.	0.6	0
5	Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 318-331.	3.7	20
6	Pelvic floor behavioral treatment for fecal incontinence and constipation in quiescent inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 807-813.	0.6	2
7	Long-Term Outcome of Multidisciplinary Versus Standard Gastroenterologist Care for Functional Gastrointestinal Disorders: A Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2102-2111.e9.	2.4	14
8	Non-invasive Serological Monitoring for Crohn's Disease Postoperative Recurrence. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1797-1807.	0.6	10
9	Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy. <i>Gut</i> , 2021, 70, 2210-2211.	6.1	12
10	Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 344-361.	1.4	11
11	Elucidation of <i>Proteus mirabilis</i> as a Key Bacterium in Crohn's Disease Inflammation. <i>Gastroenterology</i> , 2021, 160, 317-330.e11.	0.6	58
12	Low failure to attend rates and increased clinic capacity with Telehealth: A highly effective outpatient model that should continue beyond the COVID-19 pandemic. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1136-1137.	1.4	1
13	Determinants of long-term function and general well-being in patients with an ileoanal pouch. <i>JGH Open</i> , 2021, 5, 91-98.	0.7	5
14	Sa513 FOOD AS A RISK FACTOR FOR THE DEVELOPMENT AND PERPETUATION OF CROHN'S DISEASE. AN INTERNATIONAL CASE-CONTROL STUDY OF FOOD AND FOOD ADDITIVE INTAKE FROM BIRTH TILL NOW. THE ENIGMA STUDY.. <i>Gastroenterology</i> , 2021, 160, S-530.	0.6	1
15	Novel strain-level resolution of Crohn's disease mucosa-associated microbiota via an ex vivo combination of microbe culture and metagenomic sequencing. <i>ISME Journal</i> , 2021, 15, 3326-3338.	4.4	11
16	Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 249-266.	1.9	9
17	Letter: tofacitinib in biologic-experienced ulcerative colitis—a single-centre real-world experience in Australia. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 532-533.	1.9	2
18	Fecal microbiota transplantation therapy in Crohn's disease: Systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2672-2686.	1.4	35

#	ARTICLE	IF	CITATIONS
19	Approach to Dietary Restriction in Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	0
20	Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 810-820.	1.9	22
21	The gut microbiota and gut disease. <i>Internal Medicine Journal</i> , 2021, 51, 1594-1604.	0.5	6
22	Long-term outcomes of perianal fistulizing Crohn's disease in the biologic era. <i>JGH Open</i> , 2021, 5, 235-241.	0.7	4
23	Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 93-102.	0.9	20
24	Delivery of care for functional gastrointestinal disorders: A systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 204-210.	1.4	17
25	Magnetic resonance enterography for predicting the clinical course of Crohn's disease strictures. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 980-987.	1.4	15
26	Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE). <i>Gut</i> , 2020, 69, 83-91.	6.1	85
27	Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1551-1562.	1.9	38
28	Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 890-899.	3.7	64
29	Defined microbiota transplant restores Th17/ROR $\gamma$ <sup>3t</sup> regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21536-21545.	3.3	58
30	Luminal microbiota related to Crohn's disease recurrence after surgery. <i>Gut Microbes</i> , 2020, 11, 1713-1728.	4.3	22
31	Simple water-based tacrolimus enemas for refractory proctitis. <i>JGH Open</i> , 2020, 4, 561-564.	0.7	7
32	Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2020, 69, 801-810.	6.1	52
33	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1381-1392.	2.4	161
34	Processed food affects the gut microbiota: The revolution has started. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 6-7.	1.4	7
35	Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. <i>Cell Host and Microbe</i> , 2020, 27, 823-829.e3.	5.1	110
36	Gut-Directed Pelvic Floor Behavioral Treatment for Fecal Incontinence and Constipation in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 620-626.	0.9	8

#	ARTICLE	IF	CITATIONS
37	Outcome of hospital outpatient treatment of functional gastrointestinal disorders. Internal Medicine Journal, 2019, 49, 225-231.	0.5	16
38	Su1994 " The Common Food Additives Sodium Sulfite and Polysorbate 80 Have a Profound Inhibitory Effect on the Commensal, Anti-Inflammatory Bacterium Faecalibacterium Prausnitzii. the ENIGMA Study. Gastroenterology, 2019, 156, S-684-S-685.	0.6	2
39	P849 Urease-positive proteobacteria in Crohn's disease identified by novel ex vivo mucosal microbe culture combined with metagenomic sequencing (MC-MGS): the ENIGMA study. Journal of Crohn's and Colitis, 2019, 13, S548-S549.	0.6	1
40	261 " Proteus is a Key Candidate in the Pathogenesis of Crohn's Disease: Mucosa, Stool Genomics and Functional Analysis: the Enigma Study. Gastroenterology, 2019, 156, S-50.	0.6	2
41	Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Alimentary Pharmacology and Therapeutics, 2019, 49, 354-363.	1.9	87
42	Defining Optimal Care for Functional Gut Disorders - Multi-Disciplinary Versus Standard Care: A Randomized Controlled Trial Protocol. Contemporary Clinical Trials, 2019, 84, 105828.	0.8	2
43	DOP81 Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn's disease. Journal of Crohn's and Colitis, 2019, 13, S078-S079.	0.6	2
44	P575 Simple novel tacrolimus enemas are very effective in severe refractory proctitis. Journal of Crohn's and Colitis, 2019, 13, S402-S402.	0.6	0
45	P195 MRI is predictive of, and anti-TNF treatment changes, the clinical course of Crohn's disease strictures. Journal of Crohn's and Colitis, 2019, 13, S188-S188.	0.6	0
46	P852 Characterisation of Crohn's disease mucosa-associated microbiota by a novel combination of microbe culture and metagenomic sequencing (MC-MGS): the ENIGMA study. Journal of Crohn's and Colitis, 2019, 13, S550-S550.	0.6	0
47	P837 The common food additives sodium sulfite and polysorbate 80 have a profound inhibitory effect on the commensal, anti-inflammatory bacterium Faecalibacterium prausnitzii: the ENIGMA study. Journal of Crohn's and Colitis, 2019, 13, S542-S543.	0.6	5
48	Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. Gastroenterology, 2019, 156, 1440-1454.e2.	0.6	290
49	Systematic review: Pelvic floor muscle training for functional bowel symptoms in inflammatory bowel disease. JGH Open, 2019, 3, 494-507.	0.7	5
50	P834 Proteus is a key candidate in the pathogenesis of Crohn's disease: mucosa, stool genomics and functional analysis: the ENIGMA study. Journal of Crohn's and Colitis, 2019, 13, S541-S541.	0.6	1
51	Population Density and Risk of Inflammatory Bowel Disease: A Prospective Population-Based Study in 13 Countries or Regions in Asia-Pacific. American Journal of Gastroenterology, 2019, 114, 107-115.	0.2	172
52	Urbanization and the gut microbiota in health and inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 440-452.	8.2	187
53	Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease. Journal of Crohn's and Colitis, 2018, 12, 653-661.	0.6	22
54	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology, 2018, 155, 76-87.	0.6	34

#	ARTICLE	IF	CITATIONS
55	Editorial: treating strictures in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1312-1313.	1.9	1
56	The gut microbiota: cause and cure of gut diseases. <i>Medical Journal of Australia</i> , 2018, 209, 312-317.	0.8	10
57	OP019 In faecal microbiota transplantation (FMT) for ulcerative colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short-chain fatty acid production are associated with remission (FOCUS study). <i>Journal of Crohn's and Colitis</i> , 2018, 12, S013-S014.	0.6	1
58	Variants in <i>ACTG2</i> underlie a substantial number of Australasian patients with primary chronic intestinal pseudo-obstruction. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13371.	1.6	23
59	P260 Point of Care Ultrasound (POCUS) when performed by gastroenterologists with 200 supervised scans is accurate and clinically useful for patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S232-S232.	0.6	1
60	<i>Proteus</i> spp. as Putative Gastrointestinal Pathogens. <i>Clinical Microbiology Reviews</i> , 2018, 31, .	5.7	111
61	Relations between symptom severity, illness perceptions, visceral sensitivity, coping strategies and well-being in irritable bowel syndrome guided by the common sense model of illness. <i>Psychology, Health and Medicine</i> , 2017, 22, 524-534.	1.3	43
62	Visceral adiposity predicts postoperative Crohn's disease recurrence. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1255-1264.	1.9	80
63	Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2017, 389, 1218-1228.	6.3	908
64	Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1180-1199.	0.6	323
65	Long-term outcome of sacral neuromodulation for chronic refractory constipation. <i>Techniques in Coloproctology</i> , 2017, 21, 277-286.	0.8	33
66	Editorial: visceral fat as a predictor of postoperative recurrence of Crohn's disease—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1552-1553.	1.9	0
67	P589 Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S380-S381.	0.6	0
68	Serologic antibodies in relation to outcome in postoperative Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1195-1203.	1.4	21
69	Rapid changes in epidemiology of inflammatory bowel disease. <i>Lancet, The</i> , 2017, 390, 2741-2742.	6.3	60
70	Microbial Factors Associated with Postoperative Crohn's Disease Recurrence. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 191-203.	0.6	86
71	Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease. <i>Intestinal Research</i> , 2016, 14, 152.	1.0	12
72	Comparison of Fecal Inflammatory Markers in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1086-1094.	0.9	21

#	ARTICLE	IF	CITATIONS
73	Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab- authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 170-171.	1.9	0
74	312 The First Validated Post-Operative Endoscopic Crohns Disease Index: The POCER Index. Identification of Key Endoscopic Prognostic Factors. <i>Gastroenterology</i> , 2016, 150, S72.	0.6	8
75	Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia. <i>Gastroenterology</i> , 2016, 150, 86-95.e3.	0.6	94
76	Cost-effectiveness of Crohn's disease post-operative care. <i>World Journal of Gastroenterology</i> , 2016, 22, 3860.	1.4	9
77	Reply. <i>Gastroenterology</i> , 2015, 148, 856-857.	0.6	0
78	Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients – a POCER study analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 867-879.	1.9	115
79	Recent Advances in Characterizing the Gastrointestinal Microbiome in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	157
80	Donor Recruitment for Fecal Microbiota Transplantation. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1600-1606.	0.9	122
81	Impact of Drug Therapy and Surgery on Quality of Life in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1187-1194.	0.9	65
82	Prevalence of mental health disorders in inflammatory bowel disease: an Australian outpatient cohort. <i>Clinical and Experimental Gastroenterology</i> , 2015, 8, 197.	1.0	28
83	Effect of Intestinal Resection on Quality of Life in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 452-462.	0.6	30
84	Reply. <i>Gastroenterology</i> , 2015, 148, 1475-1476.	0.6	1
85	Crohn's disease management after intestinal resection: a randomised trial. <i>Lancet</i> , 2015, 385, 1406-1417.	6.3	475
86	Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery. <i>Gastroenterology</i> , 2015, 148, 938-947.e1.	0.6	241
87	Development of the Lönnemann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2015, 148, 52-63.e3.	0.6	257
88	Association between specific mucosa-associated microbiota in Crohn's disease at the time of resection and subsequent disease recurrence: A pilot study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 268-278.	1.4	137
89	Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. <i>Gut</i> , 2015, 64, 1063-1071.	6.1	320
90	A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. <i>Gut</i> , 2014, 63, 1381-1392.	6.1	317

#	ARTICLE	IF	CITATIONS
91	Outcome of behavioural treatment for idiopathic chronic constipation. Internal Medicine Journal, 2014, 44, 858-864.	0.5	8
92	Exploration of Health Status, Illness Perceptions, Coping Strategies, and Psychological Morbidity in Stoma Patients. Journal of Wound, Ostomy and Continence Nursing, 2014, 41, 573-580.	0.6	28
93	Mesalamine Did Not Prevent Recurrent Diverticulitis in Phase 3 Controlled Trials. Gastroenterology, 2014, 147, 793-802.	0.6	91
94	925j Optimising post-operative Crohn's disease management: best drug therapy alone versus colonoscopic monitoring with treatment step-up. The POCER study.. Gastroenterology, 2013, 144, S-164.	0.6	17
95	Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2013, 37, 438-444.	1.9	37
96	Postoperative recurrence of Crohn's disease: impact of endoscopic monitoring and treatment step-up. Colorectal Disease, 2013, 15, 187-197.	0.7	34
97	Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn's and Colitis Epidemiology Study. Gastroenterology, 2013, 145, 158-165.e2.	0.6	633
98	Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1595-1599.	1.4	39
99	First Prospective, Population-Based Inflammatory Bowel Disease Incidence Study in Mainland of China. Inflammatory Bowel Diseases, 2013, 19, 1.	0.9	94
100	Intestine mucosal IL-22 is reduced following oral probiotic administration: implications on epithelial barrier repair. FASEB Journal, 2013, 27, 944.2.	0.2	0
101	Long-term MRI-guided combined anti-TNF- $\alpha$ and thiopurine therapy for Crohn's perianal fistulas. Inflammatory Bowel Diseases, 2012, 18, 1825-1834.	0.9	114
102	1161 Adalimumab Prevents Post-Operative Crohn's Disease Recurrence, and is Superior to Thiopurines: Early Results From the POCER Study. Gastroenterology, 2012, 142, S-212.	0.6	13
103	Postoperative recurrent luminal Crohn's Disease: A systematic review. Inflammatory Bowel Diseases, 2012, 18, 758-777.	0.9	162
104	Serological Antibodies in Inflammatory Bowel Disease: A Systematic Review. Inflammatory Bowel Diseases, 2012, 18, 1340-1355.	0.9	164
105	Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus Melbourne. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 919-927.	1.4	34
106	Oral Bisacodyl Is Effective and Well-Tolerated in Patients With Chronic Constipation. Clinical Gastroenterology and Hepatology, 2011, 9, 577-583.	2.4	166
107	Diagnosis and treatment of chronic constipation - a European perspective. Neurogastroenterology and Motility, 2011, 23, 697-710.	1.6	239
108	Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 306-317.	1.9	39

#	ARTICLE	IF	CITATIONS
109	Preliminary examination of the relations between disease activity, illness perceptions, coping strategies, and psychological morbidity in Crohn's disease guided by the common sense model of illness. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2551-2557.	0.9	92
110	Practical application of anti-TNF therapy for luminal Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2366-2391.	0.9	18
111	Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. <i>Gut</i> , 2011, 60, 923-929.	6.1	288
112	Survey of laxative use by adults with self-defined constipation in South America and Asia: a comparison of six countries. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 274-284.	1.9	52
113	PTH-034...Stress-induced immunomodulation in irritable bowel syndrome suppresses Th1 and Th2 cytokines. <i>Gut</i> , 2010, 59, A136.2-A136.	6.1	0
114	Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 15-22.	0.9	88
115	Sacral nerve stimulation for intractable constipation. <i>Gut</i> , 2010, 59, 333-340.	6.1	229
116	Prospective Evaluation of Anti-Tumor Necrosis Factor Therapy Guided by Magnetic Resonance Imaging for Crohn's Perineal Fistulas. <i>American Journal of Gastroenterology</i> , 2009, 104, 2973-2986.	0.2	145
117	Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial. <i>American Journal of Gastroenterology</i> , 2009, 104, 1170-1179.	0.2	83
118	Effect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1-8.	0.9	78
119	Mechanisms of action of probiotics: Recent advances. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 300-310.	0.9	448
120	Therapeutic strategies for the management of ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 935-950.	0.9	65
121	Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1599-1604.	0.9	93
122	Improving the efficacy of sacral nerve stimulation for faecal incontinence by alteration of stimulation parameters. <i>British Journal of Surgery</i> , 2009, 96, 778-784.	0.1	47
123	Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 757-766.	1.9	49
124	W1096 Results from An Open-Label Extension of CHARM: Steroid-Free Remission in Patients with Crohn's Disease Who Received Adalimumab Therapy for At Least 3 Years. <i>Gastroenterology</i> , 2009, 136, A-653.	0.6	4
125	Clinical and surgical recurrence of Crohn's disease after ileocolonic resection in a specialist unit. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 551-557.	0.8	45
126	Adalimumab Therapy maintains meaningful rates of steroid-free remission in patients with Crohn's Disease for up to 3 Years of Therapy: Results From an Open-Label Extension of CHARM. <i>Inflammatory Bowel Diseases</i> , 2009, 15, S41-S42.	0.9	0

#	ARTICLE	IF	CITATIONS
127	Perianal Fistulizing Crohn's Disease: A Call to Action. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 7-10.	2.4	57
128	Management of Postoperative Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 1029-1035.	0.2	59
129	MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S24.	0.9	0
130	Steroid-Free remission in response to Adalimumab therapy over 2 years in patients with Crohn's Disease: Results From open-label extension of the CHARM trial. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S33.	0.9	0
131	Satisfaction with therapy among patients treated with MMX™ mesalamine for maintenance of remission in patients with mild-to-moderate ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S24.	0.9	0
132	Mesenteric dendritic cells from germ-free mice cause less T-cell stimulation but still induce $\alpha$ 4 $\beta$ 7 integrin. <i>Microbial Ecology in Health and Disease</i> , 2007, 19, 171-183.	3.8	3
133	Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis. <i>Gastroenterology</i> , 2007, 132, 66-75.	0.6	325
134	American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21-23, 2006. <i>Gastroenterology</i> , 2007, 133, 312-339.	0.6	197
135	Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 129-134.	0.9	64
136	Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 557-567.	1.9	79
137	Pharmacological modulation of gut mucosal and large vessel blood flow. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 693-702.	1.9	6
138	Clinical Case: Chronic Constipation. <i>Gastroenterology</i> , 2006, 131, 233-239.	0.6	12
139	Review article: biological drugs in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 80-89.	1.9	17
140	Debate: Should Mesalamine Be Used in Crohn's Disease?. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 616-617.	0.9	5
141	Lateral division of the puborectalis muscle in the management of severe constipation. <i>British Journal of Surgery</i> , 2005, 75, 661-663.	0.1	88
142	Management of idiopathic megarectum and megacolon. <i>British Journal of Surgery</i> , 2005, 78, 899-900.	0.1	32
143	Tegaserod for the Treatment of Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Multinational Study. <i>American Journal of Gastroenterology</i> , 2005, 100, 362-372.	0.2	187
144	A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2005, 129, 807-818.	0.6	571

#	ARTICLE	IF	CITATIONS
145	Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. <i>New England Journal of Medicine</i> , 2004, 350, 876-885.	13.9	2,026
146	Early surgical intervention in ulcerative colitis. <i>Gut</i> , 2004, 53, 308-309.	6.1	3
147	Maintaining remission of ulcerative colitis with the probiotic <i>Escherichia coli</i> Nissle 1917 is as effective as with standard mesalazine. <i>Gut</i> , 2004, 53, 1617-1623.	6.1	1,012
148	Chronic active disease and maintaining remission in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 102-105.	1.9	9
149	Anorexia nervosa in gastrointestinal practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1135-1142.	0.8	33
150	Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 387-393.	1.9	140
151	Randomized controlled trial of biofeedback for fecal incontinence. <i>Gastroenterology</i> , 2003, 125, 1320-1329.	0.6	383
152	Constipation and its management. <i>BMJ: British Medical Journal</i> , 2003, 327, 459-460.	2.4	43
153	Slow transit constipation: more than one disease?. <i>Gut</i> , 2002, 51, 610-610.	6.1	4
154	Short-term Effects of Sacral Nerve Stimulation for Idiopathic Slow Transit Constipation. <i>World Journal of Surgery</i> , 2002, 26, 166-170.	0.8	124
155	Maintenance of remission in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 21-24.	1.9	26
156	The complexity of drug development for irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 343-351.	1.9	52
157	Outcome of biofeedback for faecal incontinence. <i>British Journal of Surgery</i> , 2002, 86, 1159-1163.	0.1	137
158	Permanent sacral nerve stimulation for treatment of idiopathic constipation. <i>British Journal of Surgery</i> , 2002, 89, 882-888.	0.1	168
159	Double-blind placebo-controlled crossover study of sacral nerve stimulation for idiopathic constipation. <i>British Journal of Surgery</i> , 2002, 89, 1570-1571.	0.1	115
160	Pharmacological treatment of irritable bowel syndrome--from concept to sales. <i>The European Journal of Surgery Supplement: = Acta Chirurgica Supplement</i> , 2002, , 10-5.	0.2	1
161	Investigation of faecal incontinence. <i>British Journal of Hospital Medicine</i> , 2001, 62, 533-537.	0.3	9
162	Non-surgical management of faecal incontinence. <i>British Journal of Hospital Medicine</i> , 2001, 62, 538-541.	0.3	40

#	ARTICLE	IF	CITATIONS
163	Response to a behavioural treatment, biofeedback, in constipated patients is associated with improved gut transit and autonomic innervation. <i>Gut</i> , 2001, 49, 214-219.	6.1	108
164	Predictive Value of Impaired Evacuation at Proctography in Diagnosing Anismus. <i>American Journal of Roentgenology</i> , 2001, 177, 633-636.	1.0	86
165	Psychological Morbidity in Women With Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2000, 95, 2852-2857.	0.2	74
166	Why the enteric nervous system is important to clinicians. <i>Gut</i> , 2000, 47, 8iv-9.	6.1	4
167	Intestinal pseudo-obstruction. <i>Gut</i> , 2000, 47, 84iv-84.	6.1	7
168	Prospective Assessment of Accuracy of Endoanal MR Imaging and Endosonography in Patients with Fecal Incontinence. <i>American Journal of Roentgenology</i> , 2000, 175, 741-745.	1.0	109
169	Prospective comparison of faecal incontinence grading systems. <i>Gut</i> , 1999, 44, 77-80.	6.1	1,157
170	Biofeedback provides long term benefit for patients with intractable, slow and normal transit constipation. <i>Gut</i> , 1998, 42, 517-521.	6.1	177
171	Fortnightly review : Faecal incontinence. <i>BMJ: British Medical Journal</i> , 1998, 316, 528-532.	2.4	126
172	The role of psychosocial factors in functional gut disease. <i>The European Journal of Surgery Supplement: = Acta Chirurgica Supplement</i> , 1998, , 37-40.	0.2	1
173	Contribution of gastrointestinal transit and pouch characteristics in determining pouch function.. <i>Gut</i> , 1997, 40, 790-793.	6.1	24
174	Magnetic resonance imaging of the pelvic floor in patients with obstructed defaecation. <i>British Journal of Surgery</i> , 1997, 84, 1555-1558.	0.1	51
175	Chronic pelvic pain in women - gastroenterological, gynaecological or psychological?. <i>International Journal of Colorectal Disease</i> , 1997, 12, 57-62.	1.0	27
176	A radiopaque marker technique for measuring gastrointestinal transit in subjects with an ileostomy. <i>Digestive Diseases and Sciences</i> , 1996, 41, 2302-2306.	1.1	7
177	Electrogastrography in chronic intestinal pseudoobstruction. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1292-1297.	1.1	42
178	Primary and Secondary Disorders of Gut Muscle and Nerve. <i>Scandinavian Journal of Gastroenterology</i> , 1996, 31, 91-93.	0.6	6
179	Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. <i>Journal of Neurology</i> , 1995, 242, 105-108.	1.8	149
180	Controlled randomised trial of visual biofeedback versus muscle training without a visual display for intractable constipation.. <i>Gut</i> , 1995, 37, 95-99.	6.1	114

#	ARTICLE	IF	CITATIONS
181	Bowel dysfunction: a pathogenic factor in uterovaginal prolapse and urinary stress incontinence. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1994, 101, 147-152.	1.1	207
182	Obstetric damage and faecal incontinence. <i>Lancet, The</i> , 1994, 344, 730-733.	6.3	313
183	The small intestine and colon. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1993, 20, 362-3.	2.2	2
184	The management of constipation in adults. <i>Alimentary Pharmacology and Therapeutics</i> , 1993, 7, 487-500.	1.9	34
185	Idiopathic Constipation: Any Movement?. <i>Scandinavian Journal of Gastroenterology</i> , 1992, 27, 106-109.	0.6	5
186	Observation on the characteristics of stimulated defaecation in severe idiopathic constipation. <i>International Journal of Colorectal Disease</i> , 1992, 7, 197-201.	1.0	78
187	The normal range and a simple diagram for recording whole gut transit time. <i>International Journal of Colorectal Disease</i> , 1992, 7, 15-17.	1.0	136
188	Drug management of ulcerative colitis.. <i>BMJ: British Medical Journal</i> , 1992, 305, 35-38.	2.4	6
189	ANORECTAL PHYSIOLOGY AND PATHOLOGY. <i>ANZ Journal of Surgery</i> , 1991, 61, 832-838.	0.3	1
190	Steroid hormone abnormalities in women with severe idiopathic constipation.. <i>Gut</i> , 1991, 32, 80-84.	6.1	42
191	Evaluation of the intrinsic innervation of the internal anal sphincter using electrical stimulation.. <i>Gut</i> , 1989, 30, 935-938.	6.1	24
192	Bowel function and transit rate during the menstrual cycle.. <i>Gut</i> , 1989, 30, 605-608.	6.1	84
193	Rectodynamics "quantifying rectal evacuation. <i>International Journal of Colorectal Disease</i> , 1989, 4, 161-163.	1.0	43
194	Rectal sensation, the rectoanal reflex, and faecal incontinence. <i>International Journal of Colorectal Disease</i> , 1988, 3, 232-233.	1.0	0
195	Dynamic scanning defines a colonic defect in severe idiopathic constipation.. <i>Gut</i> , 1988, 29, 1085-1092.	6.1	63
196	The surgical treatment of severe idiopathic constipation. <i>International Journal of Colorectal Disease</i> , 1987, 2, 229-235.	1.0	19
197	Childhood antibiotics as a risk factor for Crohn's disease: The <sc>ENIGMA</sc> International Cohort Study. <i>JGH Open</i> , 0, , .	0.7	2